Value
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 5.8 |
| P/S | 8.9 |
| EV/EBITDA | 6.6 |
| Fwd P/E | 9.6 |
| PEG | 3.2 |
| Analyst target | 6.0 |
- ▸Forward P/E: 8.1x
- ▸PEG: 3.78
SNY · Why this verdict
Why Sanofi (SNY) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.7/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Sanofi is a large pharmaceutical company with strong 16% operating margins, 221% free cash flow conversion, and 3 of 4 recent earnings beats, but faces a confirmed death cross with falling on-balance volume and a dividend payout ratio of 552% that appears structurally unsustainable.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Sanofi earns 16% operating margins and converts 221% of net income to free cash flow — meaning the company generates more than twice its reported profits in actual cash, reflecting a capital-light pharmaceutical business model with strong recurring royalty and product cash flows. Quality breakdown | Free cash flow conversion remains above 150% of net income for at least 3 of the next 4 reported periods. | →Stable |
| CounterA 221% FCF-to-income ratio can reflect non-cash charges (depreciation, amortization of acquired intangibles) that inflate stated conversion; the underlying cash generation may be more modest than it appears. | ||
Sanofi has beaten analyst earnings estimates in 3 of the last 4 quarters with an average positive surprise of 3.4%, demonstrating consistent execution across a large and diversified pharmaceutical portfolio. Earnings | The company delivers at least 2 more earnings beats over the next 4 quarters, maintaining positive average surprises above 2%. | ↓Deteriorating |
| CounterA growth score of 2.0 out of 10 reflects weak underlying expansion momentum, and the single miss of -9% in July 2025 suggests the company is vulnerable to therapeutic area-specific setbacks. | ||
The stock has triggered a confirmed death cross with a 200-day moving average slope of -1.1% over 30 days, falling on-balance volume, and an RSI of 48 — signaling a technically negative intermediate-term trend despite improving MACD. Momentum breakdown | Price must recover above the 200-day moving average and sustain that level for at least 30 consecutive days for the downtrend thesis to be invalidated. | ↓Deteriorating |
| CounterMACD is improving and RSI is at 48 (neutral), and the recovery pattern setup suggests selling pressure may be exhausting — MACD can often inflect ahead of price recovery in pharmaceutical stocks. | ||
Sanofi's dividend payout ratio of 552% of earnings — though the high FCF conversion may partially offset this — is flagged as a yield trap where the headline dividend yield may not be sustainably covered by reported net income, creating risk of a dividend reduction. Catalyst breakdown | Dividend payout ratio as a percentage of free cash flow remains below 100% over the next 12 months, confirming the dividend is covered by actual cash generation. | ↓Deteriorating |
| CounterGiven the 221% FCF-to-net-income ratio, the 552% payout ratio relative to net income may be misleading — on a cash basis the dividend may be well-covered, and large pharmaceutical companies rarely cut dividends without a major earnings collapse. | ||
Sanofi earns 16% operating margins and converts 221% of net income to free cash flow — meaning the company generates more than twice its reported profits in actual cash, reflecting a capital-light pharmaceutical business model with strong recurring royalty and product cash flows.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 150% of net income for at least 3 of the next 4 reported periods.
CounterA 221% FCF-to-income ratio can reflect non-cash charges (depreciation, amortization of acquired intangibles) that inflate stated conversion; the underlying cash generation may be more modest than it appears.
Sanofi has beaten analyst earnings estimates in 3 of the last 4 quarters with an average positive surprise of 3.4%, demonstrating consistent execution across a large and diversified pharmaceutical portfolio.
↓DeterioratingEarnings
- Expectation
- The company delivers at least 2 more earnings beats over the next 4 quarters, maintaining positive average surprises above 2%.
CounterA growth score of 2.0 out of 10 reflects weak underlying expansion momentum, and the single miss of -9% in July 2025 suggests the company is vulnerable to therapeutic area-specific setbacks.
The stock has triggered a confirmed death cross with a 200-day moving average slope of -1.1% over 30 days, falling on-balance volume, and an RSI of 48 — signaling a technically negative intermediate-term trend despite improving MACD.
↓DeterioratingMomentum breakdown
- Expectation
- Price must recover above the 200-day moving average and sustain that level for at least 30 consecutive days for the downtrend thesis to be invalidated.
CounterMACD is improving and RSI is at 48 (neutral), and the recovery pattern setup suggests selling pressure may be exhausting — MACD can often inflect ahead of price recovery in pharmaceutical stocks.
Sanofi's dividend payout ratio of 552% of earnings — though the high FCF conversion may partially offset this — is flagged as a yield trap where the headline dividend yield may not be sustainably covered by reported net income, creating risk of a dividend reduction.
↓DeterioratingCatalyst breakdown
- Expectation
- Dividend payout ratio as a percentage of free cash flow remains below 100% over the next 12 months, confirming the dividend is covered by actual cash generation.
CounterGiven the 221% FCF-to-net-income ratio, the 552% payout ratio relative to net income may be misleading — on a cash basis the dividend may be well-covered, and large pharmaceutical companies rarely cut dividends without a major earnings collapse.
Per-dimension breakdown
Quality
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.9 |
| ROA | 3.4 |
| Gross margin | 10.0 |
| Op margin | 8.4 |
| Net margin | 4.0 |
| Current ratio | 3.9 |
| FCF quality | 10.0 |
| Moat | 7.1 |
| Rule of 40 | 5.5 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 159% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
3.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.2 |
| EPS growth | 0.0 |
Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 2.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -1.9%/30d — confirmed downtrend
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.9 |
| Price target | 8.3 |
| erm sentiment | 4.7 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 27%
Insider
5.0/10data confidence 50%Peer rank
6.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.8 |
| quality rank | 2.6 |
| growth rank | 8.8 |
- ▸Industry growth leader
- ▸Conservative debt levels
Technical
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.3 |
| 52w position | 6.7 |
Risk (lower is worse)
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.7 |
| days to cover | 7.3 |
| volatility | 7.6 |
| put call | 10.0 |
| implied vol | 7.1 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 8.6 |
- ▸Above max pain $25
Catalyst
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 6.0 |
| dividend safety | 4.8 |
- ▸Perfect beat streak: 4Q
- ▸Earnings in 1 day
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Earnings in 1 day. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (6)
- MOMENTUM:6.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:1.4<1.5@spot
- EARNINGS_PROXIMITY:1d<=7d
Warning (1)
- DEATH_CROSS:momentum=6.0>=5.0 recovering
Reward-to-Risk
1.39
Upside
+10.4%
Downside
7.5%
Sizing output
STARTER
SetupRecovery — Death cross but MACD improving, RSI 63
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings in 1 day. Wait until post-earnings. The 10-dimension scores remain Risk (lower is worse) at 7.9 (strongest), but ASYMMETRY:1.4<1.5@spot also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Risk (lower is worse) at 7.9, Sentiment at 6.8, and Peer rank at 6.8; the weakest are Technical at 2.5, Growth at 3.1, and Insider at 5.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 1.39 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Margins Exceptional Cash Conversion
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive quarters, signaling the cash quality advantage is eroding.
- P2Three Consecutive Earnings Beats
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, indicating the execution consistency is breaking down.
- P3Death Cross Confirmed Downtrend
Trip ifPrice drops below $40.00, more than 8% below the current $43.80, confirming the downtrend has accelerated rather than stabilized.
- P4Dividend Payout 552pct Sustainability
Trip ifThe company announces a dividend cut of more than 20% from current levels, or earnings coverage of the dividend falls below 50% on a trailing twelve-month basis.